MedTrace Logo

VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia

NCT00354276 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2014-01-10

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving VNP40101M followed by cytarabine may kill more cancer cells.

PURPOSE: This phase II trial is studying how well VNP40101M followed by cytarabine works in treating older patients with acute myeloid leukemia.

Conditions

Interventions

DRUG

cytarabine

DRUG

laromustine

Sponsors & Collaborators

  • Vion Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Bonny L. Johnson, RN, MSN · Vion Pharmaceuticals

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-12-31

Countries

  • United States
  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00354276 on ClinicalTrials.gov